Ultradent Donating to Southern California Fire Relief
January 14, 2025
SOUTH JORDAN, Utah January 14, 2025. Ultradent Products, Inc., a leading developer and manufacturer of high-tech dental materials, is donating 5% of U.S. sales from orders placed on Thursday, January 16, to the Red Cross to support relief efforts for those affected by the wildfires in Southern California.
“The devastation we’re witnessing in Southern California is staggering,” says Ultradent President and CEO Dirk Jeffs. “We are deeply moved by the perseverance and bravery we’ve seen during these wildfires. By pledging a portion of our sales to the Red Cross, Ultradent hopes to help bring relief and stability to impacted communities. We invite our partners in the dental community to join us in supporting the Red Cross and their admirable efforts.”
Additionally, Ultradent is offering dental supplies to affected care providers to assist in their recovery.
About Ultradent Products, Inc.
Ultradent Products, Inc., is a leading developer and manufacturer of high-tech dental materials, devices, and instruments worldwide. Ultradent’s vision is to improve oral health globally. Ultradent also works to improve the quality of life and health of individuals through financial and charitable programs. For more information about Ultradent, call 800.552.5512 or visit ultradent.com or find us on LinkedIn, Facebook, and Instagram.
###
Email Policy – Unauthorized review, use, disclosure, or distribution of this e-mail is strictly prohibited. This e-mail transmission, and any documents, files or previous e-mail messages attached to it, is intended solely for the individual or individuals to whom it is specifically addressed. If the recipient of this email is not the intended recipient, do not read, copy or distribute it or any of the information it contains. Please delete it immediately and notify us by return email or by telephone 801.572.4200.
CONTACT:
Daniel Lewis ShaLyse Walker
Communications Manager PR Manager
801.553.4777 801.553.4777
Recent News
- Biolexis Therapeutics Advances Breakthrough GLP-1 and AMPK Programs into First-in-Human Clinical Trials
- Rebel Medicine Announces Series A Financing and Investigational New Drug (IND) Application Opening to Advance Non‑Opioid Pain Therapeutic into Clinical Development
- NUSANO STABLE ISOTOPE PROGRAM ENRICHES GADOLINIUM-160 TO 99.2% PURITY
- CancerVax Targets Liver Cancers to Further Showcase Flexibility of Its Universal Platform
- Seek Labs Unveils BioSeeker™
- Halia Therapeutics Completes Enrollment in Phase 2a Clinical Trial of HT-6184 for Myelodysplastic Syndrome (MDS)
